Infliximab can be administered with care in certain conditions, but the following conditions are defined as a contraindication to infliximab administration:

- Heart failure (NYHA class III/IV) - According to the American Heart Association, TNF inhibitors may cause myocardial toxicity or exacerbate the underlying myocardial dysfunction.

- Previous hypersensitivity reaction to infliximab

- Current severe infection (sepsis, tuberculosis)

- Active infection

**Use Infliximab with Caution in the Following Conditions**

- Preexisting demyelinating disease

- Mild to moderate heart failure (NYHA class I/II)

- History of seizures

- Patients over age 65

- Uncontrolled diabetes mellitus

- Moderate to severe COPD

It is known to cause a cross-reaction with some drugs (e.g., abatacept, adalimumab, etanercept), so care is administered when the patient is on another medicine. Infliximab is contraindicated in patients who have or will require live vaccines such as cholera vaccine, live virus MMR vaccine, smallpox vaccine (live vaccinia virus), etc. Generally, vaccination should occur more than four weeks before or over three months following immunosuppressive therapy with infliximab.